Advertisement

ADVERTISEMENT

Jordan Kadish

News
Eltrombopag Demonstrated Efficacy, Relative Safety Among Patients With Low-Risk MDS and Severe Thrombocytopenia
09/20/2023
Eltrombopag demonstrated efficacy and relative safety among patients with low-risk myelodysplastic syndromes and severe thrombocytopenia, according to the phase 2 EQOL-MDS trial.
Eltrombopag demonstrated efficacy and relative safety among patients with low-risk myelodysplastic syndromes and severe thrombocytopenia, according to the phase 2 EQOL-MDS trial.
Eltrombopag demonstrated...
09/20/2023
Oncology
News
Ibrutinib Maintenance Demonstrates Feasibility Post-Induction Therapy Among Patients With Previously Treated MCL
11/28/2023
BTK inhibitor ibrutinib maintenance following induction chemo-immunotherapy was feasible and demonstrated manageable safety among certain patients with treatment-naive mantle cell lymphoma.
BTK inhibitor ibrutinib maintenance following induction chemo-immunotherapy was feasible and demonstrated manageable safety among certain patients with treatment-naive mantle cell lymphoma.
BTK inhibitor ibrutinib...
11/28/2023
Oncology
News
B-DRC Combination Treatment Yielded High Response Rates Among Patients With Waldenström Macroglobulinemia
04/19/2023
According to a recent trial, the use of bortezomib-dexamethasone, rituximab, and cyclophosphamide as a first-line combination treatment was safe and increased response rates among patients with Waldenström macroglobulinemia.
According to a recent trial, the use of bortezomib-dexamethasone, rituximab, and cyclophosphamide as a first-line combination treatment was safe and increased response rates among patients with Waldenström macroglobulinemia.
According to a recent trial, the...
04/19/2023
Oncology
News
A-HIPI Clinical Prediction Model Improves Prediction of Outcomes for Patients With Advanced-Stage Classic Hodgkin Lymphoma
03/02/2023
The development and validation of A-HIPI, a contemporary clinical prediction model for patients with advanced-stage classic Hodgkin lymphoma, improved the prediction of patient outcomes.
The development and validation of A-HIPI, a contemporary clinical prediction model for patients with advanced-stage classic Hodgkin lymphoma, improved the prediction of patient outcomes.
The development and validation...
03/02/2023
Oncology
News
Prognostic Significance of Time to POD, Ki67, and MIPI for Patients With R/R Mantle Cell Lymphoma Initiating Second-Line BTK Inhibitor Therapy
08/08/2023
Time to progression of disease, Ki67, and MIPI were strongly associated with survival outcomes among patients with R/R MCL undergoing treatment with second-line BTK inhibitors after rituximab-based chemotherapy.
Time to progression of disease, Ki67, and MIPI were strongly associated with survival outcomes among patients with R/R MCL undergoing treatment with second-line BTK inhibitors after rituximab-based chemotherapy.
Time to progression of disease,...
08/08/2023
Oncology
News
Gemtuzumab Ozogamicin Plus Intensive Chemotherapy Reduces Cumulative Incidence of Relapse Among Patients With NPM1-Mutated AML
09/18/2023
The addition of gemtuzumab ozogamicin to intensive chemotherapy reduced the cumulative incidence of relapse among patients with newly diagnosed NPM1-mutated acute myeloid leukemia, according to findings from a phase 3 trial.
The addition of gemtuzumab ozogamicin to intensive chemotherapy reduced the cumulative incidence of relapse among patients with newly diagnosed NPM1-mutated acute myeloid leukemia, according to findings from a phase 3 trial.
The addition of gemtuzumab...
09/18/2023
Oncology
News
Golidocitinib Yields Favorable Benefit-Risk Profile Among Heavily Pretreated Patients With R/R PTCL
01/31/2024
Golidocitinib, a JAK1 inhibitor, yielded a favorable benefit-risk profile among heavily pre-treated patients with R/R peripheral T-cell lymphoma, according to the phase 2 JACKPOT8 trial.
Golidocitinib, a JAK1 inhibitor, yielded a favorable benefit-risk profile among heavily pre-treated patients with R/R peripheral T-cell lymphoma, according to the phase 2 JACKPOT8 trial.
Golidocitinib, a JAK1 inhibitor,...
01/31/2024
Oncology
News
Carfilzomib, Lenalidomide, and Dexamethasone Therapy Improved PFS Among Patients With Multiple Myeloma
03/08/2023
Carfilzomib, lenalidomide, and dexamethasone therapy improved progression-free survival, but increased the risk of adverse events, among patients with newly diagnosed multiple myeloma after autologous stem cell transplant.
Carfilzomib, lenalidomide, and dexamethasone therapy improved progression-free survival, but increased the risk of adverse events, among patients with newly diagnosed multiple myeloma after autologous stem cell transplant.
Carfilzomib, lenalidomide, and...
03/08/2023
Oncology
News
Carfilzomib-Lenalidomide-Dexamethasone Regimen Compared With Bortezomib and HSCT Treatment for Patients With Multiple Myeloma
03/09/2023
Carfilzomib-lenalidomide-dexamethasone regimen did not meet non-inferiority criteria compared with bortezomib followed by HSCT and lenalidomide maintenance among patients with MM, according to a phase 2 trial.
Carfilzomib-lenalidomide-dexamethasone regimen did not meet non-inferiority criteria compared with bortezomib followed by HSCT and lenalidomide maintenance among patients with MM, according to a phase 2 trial.
...
03/09/2023
Oncology
News
Pelabresib Plus Ruxolitinib for Patients With JAK Inhibitor Naïve Myelofibrosis
05/16/2023
According to the phase 2 MANIFEST trial, the combination of pelabresib plus ruxolitinib demonstrated durable improvements in spleen volume, symptom burden, and disease-modifying activity among patients with JAK inhibitor naïve myelofibrosis.
According to the phase 2 MANIFEST trial, the combination of pelabresib plus ruxolitinib demonstrated durable improvements in spleen volume, symptom burden, and disease-modifying activity among patients with JAK inhibitor naïve myelofibrosis.
According to the phase 2...
05/16/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
AIBD logo
December 9 ⁠–⁠ December 11
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use